Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1296 • ACR Convergence 2025
Liver Biopsy Findings in Pediatric SLE: A Large Tertiary Center Experience
Meredith Rae¹, Dawn Gist², Kaylani Patel³, Krupa Mysore³, Andrea Ramirez², Marietta De Guzman² and Eyal Muscal², ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine/Texas Children's Hospital, Houston
Background/Purpose: Distinguishing lupus hepatitis (LH) from autoimmune hepatitis (AIH) in SLE is clinically challenging but critical for guiding treatment duration. The mechanisms differ; AIH results…
Abstract Number: 1240 • ACR Convergence 2025
Serum Olink Proteomics Identifies Novel Mediators of Pain in Lupus Nephritis Patients Without Extrarenal Clinical Activity
Sarah Keegan¹, Philip Carlucci², Peter Izmirly³, Erin Carter⁴, Sanchit Sanyal⁵, Brooke Cohen⁶, Jasmine Shwetar⁷, Katie Preisinger⁸, Devyn Zaminski⁶, Kristina Deonaraine⁶, Mala Masson⁹, Andrea Fava¹⁰, Judith James¹¹, Rufei Lu¹¹, Wade DeJager¹², Chaim Putterman¹³, Michael Belmont¹⁴, Richard Furie¹⁵, Maria Dall'Era¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, Jennifer Anolik¹⁹, David Wofsy²⁰, Jennifer Barnas²¹, Nir Hacohen²², Robert Clancy²³, Joel Guthridge¹¹, Brad Rovin²⁴, Michelle Petri²⁵, Jill Buyon³ and Kelly Ruggles²⁶, ¹NYU Langone, New York, ²New York University School of Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶NYU Langone, NYC, ⁷New York University School of Medicine, Department of Medicine, New York, ⁸NYU Langone, NYU Langone, ⁹NYU Langone Medical Center- Division of Rheumatology, New York, NY, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Oklahoma Medical Research Foundation, Oklahoma City, ¹³Albert Einstein College of Medicine, Safed, Israel, ¹⁴NYU Langone Health, New York, NY, ¹⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ¹⁶Division of Rheumatology, University of California, San Francisco, CA, ¹⁷Medical University of South Carolina, Johns Island, SC, ¹⁸UC San Diego, La Jolla, CA, ¹⁹University of Rochester Medical Center, Rochester, NY, ²⁰University of California San Francisco, SF, CA, ²¹University of Rochester, Rochester, NY, ²²Broad Institute of MIT Harvard, Cambridge, MA, ²³Columbia University, New York, NY, ²⁴The Ohio State University, Columbus, OH, ²⁵Johns Hopkins University School of Medicine, Timonium, MD, ²⁶NYU Grossman School of Medicine, Brooklyn, NY
Background/Purpose: For patients with lupus nephritis, active disease can be solely renal or include a range of extrarenal signs, such as arthritis or serositis, that…
Abstract Number: 1051 • ACR Convergence 2025
Mitigating Hydroxychloroquine (HCQ) Nonadherence by Clarifying Misbeliefs Using a Shared Decision-Making Tool (HCQ-SAFE©) Across Two Different Rheumatology Centers
Isabella Hartel¹, David Gazeley², Jay Patel¹, Betty Chewning³, Shelby Gomez⁴, Jessica Michaud⁵, Laura Dickmann⁶, Jon keevil⁷, Patricia Tellez-giron¹, Christie Bartels⁸ and Shivani Garg⁹, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Wisconsin, School of Pharmacy, Madison, ⁴University of Wisconsin, School of Pharmacy, Madison, WI, ⁵Medical College of Wisconsin, Milwaukee, Madison, WI, ⁶Medical College of Wisconsin, Milwaukee, Milwaukee, ⁷N/A, Madison, ⁸University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁹University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) prolongs disease-free and damage-free survival in lupus (SLE). Yet, ~80% of patients stop taking HCQ resulting in poor outcomes including early mortality.…
Abstract Number: 0939 • ACR Convergence 2025
Exploring the Mechanism of Action and Related Biomarkers of BTK Inhibitor/Degrader in Systemic Lupus Erythematosus
Chengfeng Xue¹, Jingjing Wang¹, Mengwen Huang¹, Ting Liu¹, Panpan Wang¹, Donghai Chen², Xue Wang¹, Yawei Xu¹, Yajun Gong¹, Jun Yang¹, Xiaoshan Yu¹, Ke Wang¹, Yuqing Zhu¹, Kaixuan Zhu¹, Tianqi Tang¹, Wantong Qi¹, Yaqiong Pei¹, Qiyao Zhang¹, Fugang Li², Qingyang Gu¹ and Xiangnan Qiang¹, ¹WuXi AppTec, Shanghai, China (People's Republic), ²WuXi ApptTec, Shanghai, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical and immunological manifestations. Bruton’s tyrosine kinase (BTK) is a crucial intracellular kinase in…
Abstract Number: 0707 • ACR Convergence 2025
When Can Support Lead to Missed Clinic Appointments in Patients with Systemic Lupus Erythematosus?
Samiha Karim¹, Gaobin Bao¹, Charmayne Dunlop-Thomas¹ and S. Sam Lim², ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: People from underrepresented groups with SLE can face barriers to health care and management, including discrimination and a lack of resources and social and…
Abstract Number: 0645 • ACR Convergence 2025
Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Eric Morand¹, Lucy Carter², Maria Dall'Era³, Michelle Petri⁴, Ed Vital⁵, Teri Jimenez⁶, Janine Gaiha-Rohrbach⁷, Bernard Lauwerys⁸, Annette Nelde⁹, Christian Stach¹⁰ and Ronald van Vollenhoven¹¹, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Division of Rheumatology, University of California, San Francisco, CA, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵University of Leeds, Leeds, England, United Kingdom, ⁶UCB, Raleigh, NC, ⁷Biogen, Cambridge, MA, ⁸Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, ⁹Biogen, Baar, Switzerland, ¹⁰UCB, Monheim am Rhein, Germany, ¹¹Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Dapirolizumab pegol (DZP) is a novel CD40L inhibitor with broad modulatory effects on SLE immunopathology;1,2 it consists of a polyethylene glycol (PEG)-conjugated antigen-binding fragment…
Abstract Number: 0627 • ACR Convergence 2025
Marked Decline in SLE Mortality Despite Rising Mortality in the General Population During the COVID-19 Pandemic
Omer Pamuk¹ and Ahmed Nasuhbeyoglu², ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH
Background/Purpose: Previous studies have shown a decline in systemic lupus erythematosus (SLE)-related mortality rates from 1999 to 2020. This study aimed to evaluate SLE-related mortality…
Abstract Number: 0609 • ACR Convergence 2025
Neutropenia in SLE: a Retrospective Cohort Study of Etiologies, Severity, Management, and Infection Outcomes
Eleni Papachristodoulou¹ and Vasileios Kyttaris², ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Background/Purpose: Neutropenia is a known hematologic manifestation of SLE, yet its clinical implications remain poorly defined. We conducted a retrospective study to characterize the frequency,…
Abstract Number: 0593 • ACR Convergence 2025
Genetic Risk Profiles Predict Clinical Heterogeneity in Systemic Lupus Erythematosus
Nina Oparina¹, Sarah Reid¹, Ahmne Sayadi¹, Maija-Leena Eloranta¹, Martina Frodlund², Karoline Lerang³, Andreas Jönsen⁴, Øyvind Molberg³, Solbritt Rantapää-Dahlqvist⁵, Anna Rudin⁶, Chrisopher Sjöwall⁷, Anders Bengtsson⁸, Lars Rönnblom¹ and Dag Leonard¹, ¹Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Linkoping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Department of Clinical Sciences, Lund University,, Lund, Sweden, ⁵Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁷Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁸Department of Clinical Sciences, Lund University, Lund, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical manifestations. Genetic predisposition contributes significantly to its pathogenesis, and higher genetic load is…
Abstract Number: 0793 • ACR Convergence 2025
The weight of the past: how trauma and resilience shape medication adherence in SLE
Kai Sun¹, Sofia Pozsonyiova¹, Amanda Eudy², Megan Clowse³, Rebecca Sadun¹, Mithu Maheswaranathan⁴, Jayanth Doss⁵, Nathaniel Harris⁶, Lisa Criscione-Schreiber⁴, Connor Drake⁴, Tamara Somers⁷, Ralph Snyderman⁸ and Jennifer Rogers⁴, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³Duke University, Chapel Hill, NC, ⁴Duke University School of Medicine, Durham, ⁵Division of Rheumatology and Immunology, Duke University Department of Medicine, Durham, NC, ⁶Duke University Medical Center, Durham, NC, ⁷Duke University School of Medicine, Durham, NC, ⁸Duke Center for Personalized Health Care, Durham, NC
Background/Purpose: Medication adherence in SLE is suboptimal and contributes to increased disease activity, organ damage, and mortality. Trauma exposure is common among those with SLE…
Abstract Number: 0206 • ACR Convergence 2025
Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies
Nadia Emi Aikawa¹, Julia Medeiros², Sandra G Pasoto³, Ana C Medeiros-Ribeiro³, Luciana Parente Costa Seguro⁴, Ana Paula Luppino-Assad⁵, Emily Figueiredo Neves Yuki⁶, Lissiane Guedes⁷, Clovis Artur Silva⁸ and Eloisa Bonfa⁴, ¹Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, ⁶Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Recombinant zoster vaccine (RZV), represents a major advancement in the prevention of herpes zoster in autoimmune rheumatic diseases (ARD) patients. However, RVZ efficacy depends…
Abstract Number: 1509 • ACR Convergence 2025
Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study
Shuzo Sato, Kaito Moriuchi, So Yamamoto, Hiroki Nibu, Takahito Sakamoto, Shotaro Ogawa, Kenji Saito, Yuya Sumichika, Shuhei Yoshida, Haruki Matsumoto, Jumpei Temmoku and Tomoyuki Asano, Fukushima Medical University, Fukushima, Fukushima, Japan
Background/Purpose: Past reports have shown that serositis is a risk factor for organ damage in patients with SLE. However, the distinct clinical features of newly…
Abstract Number: 2668 • ACR Convergence 2025
CD14⁺ Myeloid Cells Mediate UVB Photosensitivity in Autoimmune Skin Disease via a Spatially Resolved Inflammatory Circuit
Nazgol Haddadi¹, Khashayar Afshari¹, Yuqing Wang¹, Carolina S. Lopes¹, Chee-Huat L. Eng², Nuria Martinez-Gutierrez¹, Leah Whiteman¹, Kevin Wei³, Kirsten Frieda², Stefania Gallucci¹, Misha Rosenbach⁴, Ruth Ann Vleugels⁵, John E. Harris¹, Manuel Garber¹ and Mehdi Rashighi¹, ¹UMass Chan Medical School, Worcester, MA, ²Spatial Genomics, Inc., Pasadena, CA, ³Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Brigham and Women's Hospital, Chestnut Hill, MA
Background/Purpose: Inflammatory skin diseases vary widely in symptoms and causes. While ultraviolet (UV) light helps treat some like vitiligo and psoriasis, in conditions like cutaneous…
Abstract Number: 2597 • ACR Convergence 2025
Altered Tryptophan Metabolism in Neuropsychiatric Lupus: A Cluster Analysis to Identify Distinct Subgroups
Yang Wu¹, Shangzhu Zhang², Mengtao Li³, Christian Lood⁴ and Xiaofeng Zeng⁵, ¹¹. Chinese Academy of Medical Sciences & Peking Union Medical College; ². Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China; ³. University of Washington, Division of Rheumatology, Seattle, WA, USA, Beijing, China (People's Republic), ²Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China (People's Republic), ³Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁴University of Washington, Division of Rheumatology, Seattle, ⁵Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic)
Background/Purpose: Patients with neuropsychiatric systemic lupus erythematosus (NPSLE) experience impaired quality of life, whereas the underlying cause(s) remain unclear. The heterogeneity within NPSLE subtypes poses…
Abstract Number: 2465 • ACR Convergence 2025
CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
chunmei Wu¹, Yakai Fu², Jia Liu³, Yan Ye⁴, Ran Wang⁵, Xintong Feng³, Lianjun Shen⁶, Peiying Li⁵, Shuang Ye⁵ and Qiong Fu⁷, ¹Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ³Astrazeneca, Shanghai, China (People's Republic), ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ⁶Astrazeneca, Shanghai, Shanghai, China (People's Republic), ⁷Renji Hospital, Shanghai, Shanghai, China
Background/Purpose: GC012F (AZD0120) is a CD19/B cell maturation antigen (BCMA) dual-targeting chimeric antigen receptor T-cell (CAR-T) developed on the novel FasTCAR-T platform with next-day manufacturing,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].